Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization

Archives of Ophthalmology

Volumn 127, Issue 3, 2009, Pages 275-281

  Tatar, Olcay ^a   Adam, Annemarie ^b   Shinoda, Kei ^c   Kaiserling, Edwin ^b   Boeyden, Vicky ^d   Claes, Carl ^d   Eckardt, Claus ^e   Eckert, Tillmann ^e   Pertile, Grazia ^f   Scharioth, Gabor B ^g   Yoeruek, Efdal ^a   Szurman, Peter ^a   Bartz Schmidt, Karl Ulrich ^a   Grisanti, Salvatore ^h,i  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c National Hospital Organization   (Japan)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

^e Augenklinik der Staedtischen Kliniken   (Germany)

^f SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^g Augenzentrum Recklinghausen   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; CYTOKERATIN 18; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; KI 67 ANTIGEN; THY 1 ANTIGEN; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN; VERTEPORFIN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CELL ADHESION; CELL DENSITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; LEUKOCYTE; MACROPHAGE; MALE; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA TRANSLOCATION; SUBRETINAL NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, THY-1; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; E-SELECTIN; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; INJECTIONS; INTERCELLULAR ADHESION MOLECULE-1; LASER COAGULATION; LEUKOCYTE COUNT; LEUKOCYTES; LYMPHOCYTE ACTIVATION; MACROPHAGES; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; RETINA; RETROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 62449209255     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2008.602     Document Type: Article

References (66)

1. Congdon N, O'Colmain B, Klaver CC, et al; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-485.
2. Bressler NM; Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials: TAP report 2. Arch Ophthalmol. 2001;119(2):198-207.
3. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003;121(5):667-673.
4. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112(2):301-304.
5. Hui YN, Liang HC, Cai YS, Kirchhof B, Heimann K. Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefes Arch Clin Exp Ophthalmol. 1993;231(2):109-114.
6. Chandler DB, Rozakis G, de Juan EJ Jr, Machemer R. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol. 1985;99(6):686-690.
7. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90(6):810-816.
8. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1993;231(1):34-40.
9. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology. 1996;103(12):2099-2104.
10. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol. 1985;103(5):708-711.
11. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol. 2001;119(3):399-404.
12. Ciulla TA, Criswell MH, Danis RP, et al. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br J Ophthalmol. 2003;87(8):1032-1037.
13. Penfold PL, Wen L, Madigan MC, Gillies MC, King NJ, Provis JM. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol. 2000;121(3):458-465.
14. Penfold PL, Wen L, Madigan MC, King NJ, Provis JM. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci. 2002;43(9):3125-3130.
15. Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative AMD. Clin Exp Ophthalmol. 2001;29:188-192.
16. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol. 2004;122(12):1801-1807.
17. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341(2-3):309-315.
18. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci. 2005;46(3):1062-1068.
19. Tong JP, Lam DS, Chan WM, Choy KW, Chan KP, Pang CP. Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelial and human umbilical vein endothelial cells. Mol Vis. 2006;12:1490-1495.
20. Obata R, Inoue Y, Iriyama A, Takahashi H, Tamaki Y, Yanagi Y. Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro [published online ahead of print September 20, 2006]. Br J Ophthalmol. 2007;91(1):100-104.
21. Itakura H, Akiyama H, Hagimura N, et al. Triamcinolone acetonide suppresses interleukin-1 beta-mediated increase in vascular endothelial growth factor expression in cultured rat Muller cells [published online ahead of print July 28, 2005]. Graefes Arch Clin Exp Ophthalmol. 2006;244(2):226-231.
22. Kwak N, Okamoto N, Wood J, Campochiaro P. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41(10):3158-3164.
23. Tatar O, Shinoda K, Kaiserling E, et al. Early effects of triamcinolone on vascular endothelial growth factor and endostatin in human choroidal neovascularization. Arch Ophthalmol. 2008;126(2):193-199.
24. Carson MJ, Reilly CR, Sutcliffe JG, Lo D. Mature microglia resemble immature antigen-presenting cells. Glia. 1998;22(1):72-85.
25. Denker SP, Ji S, Dingman A, et al. Macrophages are comprised of resident brain microglia not infiltrating peripheral monocytes acutely after neonatal stroke [published online ahead of print December 22, 2006]. J Neurochem. 2007;100(4):893-904.
26. Lee WS, Jain MK, Arkonac BM, et al. Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines. Circ Res. 1998;82(8):845-851.
27. Martidis A, Miller DG, Ciulla TA, Danis RP, Moorthy RS. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther. 1999;15(5):425-428.
28. Szurman P, Kaczmarek R, Jaissle GB, et al. Influence of different purification techniques on triamcinolone yield and particle size spectrum [published online ahead of print September 28, 2006]. Graefes Arch Clin Exp Ophthalmol. 2007;245(5):689-696.
29. Bitter C, Suter K, Figueiredo V, Pruente C, Hatz K, Surber C. Preservative-free triamcinolone acetonide suspension developed for intravitreal injection. J Ocul Pharmacol Ther. 2008;24(1):62-69.
30. Tatar O, Kaiserling E, Adam A, et al. Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol. 2006;124(6):815-823.
31. Ambati J, Anand A, Fernandez S, et al. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice [published online ahead of print October 19, 2003]. Nat Med. 2003;9(11):1390-1397.
32. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells [published online ahead of print December 6, 2000]. J Biol Chem. 2001;276(10):7614-7620.
33. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocytes adhesion in vivo. Am J Pathol. 2002;160(2):501-509.
34. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990;172(6):1535-1545.
35. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87(8):3336-3343.
36. Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol. 1994;55(3):410-422.
37. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611.
38. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40(9):1891-1898.
39. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(8):3578-3585.
40. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(8):3586-3592.
41. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization [correction published in Am J Pathol. 2000;157(4):1413]. Am J Pathol. 2000;157(1):135-144.
42. Sakurai E, Taguchi H, Anand A, et al. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(6):2743-2749.
43. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;8:119-126.
44. Grossniklaus HE, Martinez JA, Brown VB, et al. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol. 1992;114(4):464-472.
45. Seregard S, Algvere PV, Berglin L. Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefes Arch Clin Exp Ophthalmol. 1994;232(6):325-329.
46. Tatar O, Adam A, Shinoda K, et al. Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to agerelated macular degeneration. Retina. 2007;27(6):713-723.
47. Yeh DC, Bula DV, Miller JW, Gragoudas ES, Arroyo JG. Expression of leukocyte adhesion molecules in human subfoveal choroidal neovascular membranes treated with and without photodynamic therapy. Invest Ophthalmol Vis Sci. 2004;45(7):2368-2373.
48. Tatar O, Shinoda K, Adam A, et al. Expression of endostatin in human choroidal neovascular membranes secondary to age-related macular degeneration [published online ahead of print April 11, 2006]. Exp Eye Res. 2006;83(2):329-338.
49. Tatar O, Shinoda K, Adam A, et al. Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes [published online ahead of print September 20, 2006]. Br J Ophthalmol. 2007;91(2):166-173.
50. Nishimura T, Goodnight R, Prendergast RA, Ryan SJ. Activated macrophages in experimental subretinal neovascularization. Ophthalmologica. 1990;200(1):39-44.
51. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature. 1987;329(6140):630-632.
52. Pavilack MA, Elner VM, Elner SG, Todd RF III, Huber AR. Differential expression of human corneal and perilimbal ICAM-1 by inflammatory cytokines. Invest Ophthalmol Vis Sci. 1992;33(3):564-573.
53. Elner SG, Elner VM, Pavilack MA, et al. Modulation and function of intercellular adhesion molecule-1 (CD54) on human retinal pigment epithelial cells. Lab Invest. 1992;66(2):200-211.
54. Platts KE, Benson MT, Rennie IG, Sharrard RM, Rees RC. Cytokine modulation of adhesion molecule expression on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1995;36(11):2262-2269.
55. Tsutsumi C, Sonoda KH, Egashira K, et al. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol. 2003;74(1):25-32.
56. Giangiacomo J, Dueker DK, Adelstein EH. Histopathology of triamcinolone in the subconjunctiva. Ophthalmology. 1987;94(2):149-153.
57. Gao H, Qiao X, Gao R, Mieler WF, McPherson AR, Holz ER. Intravitreal triamcinolone does not alter basal vascular endothelial growth factor mRNA expression in rat retina. Vision Res. 2004;44(4):349-356.
58. Hasan Q, Tan ST, Gush J, Peters SG, Davis PF. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics. 2000;105(1, pt 1):117-120.
59. Lobov IB, Rao S, Carroll TJ, et al. WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. Nature. 2005;437(7057):417-421.
60. Lang RA. Apoptosis in mammalian eye development: lens morphogenesis, vascular regression and immune privilege. Cell Death Differ. 1997;4(1):12-20.
61. Diez-Roux G, Argilla M, Makarenkova H, Ko K, Lang RA. Macrophages kill capillary cells in G1 phase of the cell cycle during programmed vascular regression. Development. 1999;126(10):2141-2147.
62. Diez-Roux G, Lang RA. Macrophages induce apoptosis in normal cells in vivo. Development. 1997;124(18):3633-3638.
63. Apte RS, Richter J, Herndon J, Ferguson TA. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med. 2006;3(8):e310.
64. Spandau UH, Sauder G, Schubert U, Hammes HP, Jonas JB. Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo. Br J Ophthalmol. 2005;89(6):745-747.
65. Tatar O, Adam A, Shinoda K, et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol. 2008;126(6):782-790.
66. Liggett PE, Colina J, Chaudhry NA, Tom D, Haffner G. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization [published online ahead of print September 1, 2006]. Am J Ophthalmol. 2006;142(6):1072-1074.